Akebia Therapeutics saw an 11% drop in stock after reporting Q4 results, with mixed analyst opinions. Revenue forecasts show a 3% decline in 2024, with losses expected to increase.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Akebia Therapeutics saw an 11% drop in stock after reporting Q4 results, with mixed analyst opinions. Revenue forecasts show a 3% decline in 2024, with losses expected to increase.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.